EA200300046A1 - QUICKLY INCREASING COMPOSITION IN VOLUME FOR RETAINING AND CONTROLLED ALLOCATION OF THERAPEUTIC AGENTS IN THE STOMACH AND MEDICAL FORMS INCLUDING THE COMPOSITION - Google Patents

QUICKLY INCREASING COMPOSITION IN VOLUME FOR RETAINING AND CONTROLLED ALLOCATION OF THERAPEUTIC AGENTS IN THE STOMACH AND MEDICAL FORMS INCLUDING THE COMPOSITION

Info

Publication number
EA200300046A1
EA200300046A1 EA200300046A EA200300046A EA200300046A1 EA 200300046 A1 EA200300046 A1 EA 200300046A1 EA 200300046 A EA200300046 A EA 200300046A EA 200300046 A EA200300046 A EA 200300046A EA 200300046 A1 EA200300046 A1 EA 200300046A1
Authority
EA
Eurasian Patent Office
Prior art keywords
composition
stomach
volume
retaining
therapeutic agents
Prior art date
Application number
EA200300046A
Other languages
Russian (ru)
Inventor
Моше Флэшнер-Барек
Е. Ицхак Лернер
Веред Розенбергер
Мазал Дахан
Израэл Маков
Original Assignee
Тева Фармасьютикал Индастриес Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Тева Фармасьютикал Индастриес Лтд. filed Critical Тева Фармасьютикал Индастриес Лтд.
Publication of EA200300046A1 publication Critical patent/EA200300046A1/en

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82B—NANOSTRUCTURES FORMED BY MANIPULATION OF INDIVIDUAL ATOMS, MOLECULES, OR LIMITED COLLECTIONS OF ATOMS OR MOLECULES AS DISCRETE UNITS; MANUFACTURE OR TREATMENT THEREOF
    • B82B3/00—Manufacture or treatment of nanostructures by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y15/00—Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors

Abstract

Данное изобретение относится к фармацевтической композиции, которую используют в лекарственной форме для орального введения больному. Композиция увеличивается в объеме при контакте с желудочной жидкостью и стимулирует задерживание лекарственной формы в желудке больного в течение продолжительного периода времени. Кроме того, данное изобретение относится к фармацевтическим лекарственным формам, содержащим активный ингредиент и фармацевтическую композицию. Формы предназначены для немедленного или контролируемого выделения активного ингредиента. Лекарственные формы можно преимущественно использовать при лечении болезни Паркинсона с помощью леводопа и лечения расстройства, связанного с повышенной активностью или недостатком внимания, с помощью метилфенидата.Международная заявка была опубликована вместе с отчетом о международном поиске.This invention relates to a pharmaceutical composition, which is used in a dosage form for oral administration to a patient. The composition increases in volume upon contact with gastric fluid and stimulates the retention of the dosage form in the patient's stomach for an extended period of time. In addition, this invention relates to pharmaceutical dosage forms containing the active ingredient and the pharmaceutical composition. Forms are intended for immediate or controlled release of the active ingredient. Dosage forms can be advantageously used in the treatment of Parkinson's disease with levodopa and the treatment of disorders associated with increased activity or lack of attention with methylphenidate. The international application was published together with an international search report.

EA200300046A 2000-06-23 2001-06-22 QUICKLY INCREASING COMPOSITION IN VOLUME FOR RETAINING AND CONTROLLED ALLOCATION OF THERAPEUTIC AGENTS IN THE STOMACH AND MEDICAL FORMS INCLUDING THE COMPOSITION EA200300046A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US21383200P 2000-06-23 2000-06-23
US21711000P 2000-07-10 2000-07-10
US22321200P 2000-08-04 2000-08-04
PCT/US2001/020134 WO2002000213A1 (en) 2000-06-23 2001-06-22 Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition

Publications (1)

Publication Number Publication Date
EA200300046A1 true EA200300046A1 (en) 2003-10-30

Family

ID=27395915

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200300046A EA200300046A1 (en) 2000-06-23 2001-06-22 QUICKLY INCREASING COMPOSITION IN VOLUME FOR RETAINING AND CONTROLLED ALLOCATION OF THERAPEUTIC AGENTS IN THE STOMACH AND MEDICAL FORMS INCLUDING THE COMPOSITION

Country Status (11)

Country Link
EP (1) EP1305021A4 (en)
JP (1) JP2004501190A (en)
KR (1) KR20030013460A (en)
AU (2) AU2001268722B8 (en)
CA (1) CA2412490A1 (en)
CZ (1) CZ2003199A3 (en)
EA (1) EA200300046A1 (en)
HU (1) HUP0301465A3 (en)
IL (1) IL153497A0 (en)
MX (1) MXPA02012793A (en)
WO (1) WO2002000213A1 (en)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7608640B2 (en) 1999-03-02 2009-10-27 Jallal Messadek Glycine betaine and its use
EP1416914A1 (en) * 2001-08-16 2004-05-12 The State of Oregon acting by and through The State Board of Higher Education on behalf of Oregon State University Expandable gastric retention device
BE1015608A6 (en) 2003-07-15 2005-06-07 Messadek Jallal TREATMENT arteritis.
US20030224045A1 (en) * 2002-05-29 2003-12-04 Chien-Hsuan Han Combination immediate release sustained release levodopa/carbidopa dosage forms
US7094427B2 (en) * 2002-05-29 2006-08-22 Impax Laboratories, Inc. Combination immediate release controlled release levodopa/carbidopa dosage forms
DE602004003577T2 (en) * 2003-04-17 2007-09-20 Jallal Messadek Floating oral formulations with controlled release of betaine
US20050113452A1 (en) * 2003-10-20 2005-05-26 Moshe Flashner-Barak Composition and dosage form for sustained effect of levodopa
JP2005132803A (en) * 2003-10-31 2005-05-26 Ono Pharmaceut Co Ltd Solid pharmaceutical preparation staying in stomach
TW200533391A (en) 2004-03-25 2005-10-16 Sun Pharmaceutical Ind Ltd Gastric retention drug delivery system
FR2874325B1 (en) * 2004-08-19 2006-10-20 Sanofi Synthelabo PHARMACEUTICAL COMPOSITION IN THE FORM OF A GASTRIC RESISTANCE COMPRESSOR CONTAINING ALFUZOSIN
WO2006050581A2 (en) 2004-11-10 2006-05-18 Jallal Messadek Betaine as agent against arthropod - or mosquito -borne diseases
WO2006086856A1 (en) 2005-02-15 2006-08-24 Messadek, Jallal Combination therapeutic compositions and method of use
WO2006113978A2 (en) 2005-04-27 2006-11-02 Jallal Messadek Insulins combinations
NL2000281C2 (en) 2005-11-02 2007-08-07 Pfizer Prod Inc Solid pharmaceutical compositions containing pregabalin.
AU2007267135B2 (en) * 2006-05-31 2013-03-07 AbbVie Pharmaceuticals GmbH Long term 24 hour intestinal administration of levodopa/carbidopa
EP1872775A1 (en) 2006-06-29 2008-01-02 Polichem S.A. Use of a hydrophilic matrix comprising a polyacrylic acid derivative, a cellulose ether and a disintegrant for the manufacture of a medicament for treating female genital disorders
CL2007002574A1 (en) * 2006-09-08 2008-05-23 Drug Tech Corp Sa Organizada B ORAL PHARMACEUTICAL COMPOSITION INCLUDING LEVODOPA IN A UNIT DOSE OF AROUND 100 TO AROUND 500 MG AND AN ADEQUATE EXCIPIENT; AND ITS USE TO TREAT PARKINSON.
WO2008039186A2 (en) * 2006-09-26 2008-04-03 Plensat, Llc Method and system for treatment of eating disorders
WO2008087882A1 (en) 2007-01-15 2008-07-24 Kissei Pharmaceutical Co., Ltd. Intragastric floating-type levodopa sustained-release preparation
KR20080076382A (en) * 2007-02-15 2008-08-20 (주)아모레퍼시픽 Controlled-release preparation containing cilostazol and process for the preparation thereof
DE102007026037A1 (en) * 2007-06-04 2008-12-11 Lts Lohmann Therapie-Systeme Ag Gastroretentive system with alginate body
JP2010534721A (en) * 2007-07-27 2010-11-11 ディポメド，インコーポレイティド Pulse type gastric retentive preparation
AU2009267052B2 (en) 2008-06-30 2013-07-11 Tocagen Inc. Formulations of 5-fluorocytosine and uses thereof
MX340249B (en) 2008-08-15 2016-07-01 Depomed Inc Gastric retentive pharmaceutical compositions for treatment and prevention of cns disorders.
AU2009311877C1 (en) * 2008-11-07 2013-08-15 Samyang Holdings Corporation Pharmaceutical composition for release control of methylphenidate
WO2012093974A1 (en) * 2011-01-06 2012-07-12 Mahmut Bilgic Improved bisphosphonate formulations
CN103385871B (en) * 2012-05-07 2017-06-23 新疆医科大学 Benserazide micro-capsule floating tablet
EP2858604B1 (en) 2012-06-07 2024-02-21 Epitomee Medical Ltd Expanded device
WO2014174388A1 (en) * 2013-03-29 2014-10-30 Wockhardt Limited Modified release pharmaceutical compositions of methylphenidate or salts thereof
JP6204141B2 (en) * 2013-04-22 2017-09-27 テイカ製薬株式会社 Oral rapidly disintegrating composition for solid preparation
WO2014176389A1 (en) * 2013-04-24 2014-10-30 Temple University - Of The Commonwealth System Of Higher Education Solid dosage form containing arabinogalactan
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
EP3782614A1 (en) 2013-10-07 2021-02-24 Impax Laboratories, LLC Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
EP3091962B1 (en) 2013-12-05 2022-06-08 Epitomee Medical Ltd. Retentive devices and systems for in-situ release of pharmaceutical active agents
JP2018506590A (en) * 2015-02-27 2018-03-08 シンギュレイト・セラピューティクス・リミテッド・ライアビリティ・カンパニーＣｉｎｇｕｌａｔｅ Ｔｈｅｒａｐｅｕｔｉｃｓ ＬＬＣ Tripulse-release activator formulation
JP6823539B2 (en) * 2017-05-26 2021-02-03 株式会社ファンケル Gastric retention tablets
US10987311B2 (en) 2017-06-16 2021-04-27 Kashiv Specialty Pharmaceuticals, Llc Extended release compositions comprising pyridostigmine
US10588863B2 (en) 2017-06-16 2020-03-17 Kashiv Biosciences, Llc Extended release compositions comprising pyridostigmine
WO2018232413A1 (en) 2017-06-16 2018-12-20 Kashiv Pharma Llc Gastroretentive dosage forms for sustained drug delivery
WO2019246145A1 (en) 2018-06-18 2019-12-26 Kashiv Biosciences, Llc Extended release compositions comprising pyridostigmine
CA3065695C (en) 2018-06-27 2021-06-01 Kashiv Biosciences, Llc Self-regulating osmotic gastroretentive drug delivery systems
JP7044649B2 (en) * 2018-06-28 2022-03-30 株式会社ファンケル Intragastric floating tablets
CA3139217A1 (en) 2019-05-14 2020-11-19 Clexio Biosciences Ltd. Treatment of nocturnal symptoms and morning akinesia in subjects with parkinson's disease
JP2023516370A (en) * 2020-03-02 2023-04-19 クラフト ヘルス プライベート リミテッド Oral dosage form for sustained drug release
US11571402B2 (en) * 2021-02-17 2023-02-07 Springworks Therapeutics, Inc. Dispersible formulations of N-((R)-2,3-dihydroxypropoly)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof
WO2022195476A1 (en) 2021-03-15 2022-09-22 Clexio Biosciences Ltd. Gastroretentive devices for assessment of intragastric conditions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4140755A (en) * 1976-02-13 1979-02-20 Hoffmann-La Roche Inc. Sustained release tablet formulations
US4167558A (en) * 1976-02-13 1979-09-11 Hoffmann-La Roche Inc. Novel sustained release tablet formulations
US4434153A (en) * 1982-03-22 1984-02-28 Alza Corporation Drug delivery system comprising a reservoir containing a plurality of tiny pills
IT1282650B1 (en) * 1996-02-19 1998-03-31 Jagotec Ag PHARMACEUTICAL TABLET, CHARACTERIZED BY A HIGH INCREASE IN VOLUME IN CONTACT WITH BIOLOGICAL LIQUIDS
JP2001510788A (en) * 1997-07-23 2001-08-07 ペリオ プロダクツ リミテッド Tannic acid polymer compositions for pharmaceutically controlled release of pharmaceutical agents into the oral cavity

Also Published As

Publication number Publication date
CZ2003199A3 (en) 2003-12-17
AU2001268722B8 (en) 2005-09-29
EP1305021A4 (en) 2009-09-23
HUP0301465A3 (en) 2006-07-28
WO2002000213A1 (en) 2002-01-03
EP1305021A1 (en) 2003-05-02
AU6872201A (en) 2002-01-08
CA2412490A1 (en) 2002-01-03
AU2001268722B2 (en) 2005-08-11
IL153497A0 (en) 2003-07-06
HUP0301465A2 (en) 2004-05-28
KR20030013460A (en) 2003-02-14
JP2004501190A (en) 2004-01-15
MXPA02012793A (en) 2004-07-30

Similar Documents

Publication Publication Date Title
EA200300046A1 (en) QUICKLY INCREASING COMPOSITION IN VOLUME FOR RETAINING AND CONTROLLED ALLOCATION OF THERAPEUTIC AGENTS IN THE STOMACH AND MEDICAL FORMS INCLUDING THE COMPOSITION
EA200300045A1 (en) COMPOSITION AND MEDICATION FORM FOR THE DETAINED GASTRIC ALLOCATION OF AENDRONATE AND / OR OTHER BIS-PHOSPHONATES
BR9909903A (en) Maximum effectiveness of substances used to improve health and well-being
BR0009016A (en) Composition of apomorphine and sildenafil
CO4600739A1 (en) ALENDRONATE BASED ORAL LIQUID FORMULATIONS
EA200601799A1 (en) HYDRAZIDE-CONTAINING COMPOUNDS - CFTR INHIBITORS AND THEIR APPLICATION
NO20043871L (en) Controlled release drug formulations containing a carrier peptide
ATE246919T1 (en) IMPROVED TRANSDERMAL THERAPEUTIC SYSTEM FOR THE TREATMENT OF PARKINSON'S DISEASE
ATE543491T1 (en) COMBINATION PREPARATION CONTAINING IBUPROFEN AND PARACETAMOL
HUP0102489A2 (en) Use of biochemical substances for a composition for the prevention and treatment of health conditions caused by constriction of smooth muscle cells in organs of the human body
HUP0401867A2 (en) Use of derivatives of valproic acid amides and 2-valproenic acid amides for the treatment or prevention of pain and/or headache disorders
ATE251901T1 (en) TRANSDERMAL THERAPEUTIC SYSTEM FOR ACHIEVEMENT OF HIGH PLASMA LEVELS OF ROTIGOTIN IN THE THERAPY OF PARKINSON'S DISEASE
IS7006A (en) Dihydrogen 3-piperidinopropiophenone and medicinal products containing said compounds
PL370529A1 (en) Use of 2-oxo-1-pyrrolidine derivatives for the preparation of a drug
RU2006139819A (en) APPLICATION OF SYMETICON FOR PATIENTS POSITIONED FOR CONSTIPATION
BG104797A (en) Use of dexmedetomi dine for sedative effect in patients in an intensive care unit
RU95101385A (en) Products containing g-csf and tnf-binding protein
RU2002122084A (en) COMBINATION OF MEDICINES, INCLUDING MIRTAZAPINE, FOR THE TREATMENT OF DEPRESSION AND RELATED DISORDERS
ATE446309T1 (en) CAPILLARY RESISTANCE IMPROVEMENT PEPTIDE SUBSTANCE, PHARMACEUTICAL COMPOSITION BASED THEREOF AND METHOD FOR USE THEREOF
MA28036A1 (en) USE OF OXCARBAZEPINE IN THE TREATMENT OF PAIN RELATED TO DIABETIC NEUROPATHY AND IN SLEEP IMPROVEMENT
LT2006024A (en) Tetrapeptide regulating blood glucose level in diabetes mellitus
RU2002124141A (en) APPLICATION OF MIRTAZAPINE FOR TREATMENT OF SLEEP DISORDERS
HUP0301408A2 (en) Methods and compositions using sulodexide for the treatment of diabetic nephropathy
BR0104586A (en) Method for treating neurodegeneration
WO2005060939A3 (en) Controlled-release pharmaceutical formulation